BrainsWay Expands Deep TMS Coverage to 70M Lives in U.S.

Event summary

BrainsWay's SWIFT Accelerated Deep TMS™ protocol now covers over 70 million lives in the U.S.
Favorable policy changes for Deep TMS treatments for MDD and OCD are driving adoption.
CEO Hadar Levy cites growing clinical evidence supporting the efficacy of SWIFT protocol.
BrainsWay leads with proprietary H-coil technology and multiple FDA-cleared indications.

The big picture

BrainsWay's expansion of Deep TMS coverage aligns with broader trends in mental health treatment, where noninvasive therapies are gaining traction. The company's strategic focus on clinical validation and stakeholder education positions it to capitalize on increasing demand for innovative psychiatric interventions. The scale of 70 million covered lives underscores the potential market impact of this development.

What we're watching

Adoption Pace: How quickly BrainsWay can convert favorable policies into actual patient treatments.
Clinical Validation: Whether the growing body of clinical evidence will sustain long-term coverage expansion.
Competitive Dynamics: The pace at which competitors develop similar noninvasive brain stimulation technologies.